Premium
Adriamycin and cisplatin for hepatoblastoma
Author(s) -
Quinn John J.,
Altman Arnold J.,
Robinson H. Thomas,
Cooke Ronald W.,
Hight Donald W.,
Foster James H.
Publication year - 1985
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19851015)56:8<1926::aid-cncr2820560805>3.0.co;2-g
Subject(s) - medicine , hepatoblastoma , discontinuation , cisplatin , doxorubicin , radiation therapy , chemotherapy , oncology , adjuvant therapy , surgery , gastroenterology
Four consecutive infants and children with hepatoblastomas were treated with a combination of Adriamycin (doxorubicin) and cisplatin. Three patients had unresectable tumors and in each there was a dramatic decrease in tumor size and serum alpha‐fetoprotein (AFP) levels. The tumors of two of these patients, including one with pulmonary metastases which cleared, were rendered resectable. The third patient's tumor remained unresectable but his AFP level returned to normal following radiotherapy. All three patients are disease‐free, and both without metastases are off therapy from 9 to 24 months. A fourth child received the combination as adjuvant therapy following resection of an embryonal hepatoblastoma and he remains disease‐free 7 months after its discontinuation. Therapy was tolerable in all patients and its principal toxicities were myelosuppression and magnesium wasting. Adriamycin and cisplatin in combination were very effective in these patients and deserve further trials, especially in unresectable and metastatic hepatoblastomas. Cancer 56: 1926‐1929, 1985.